Stroke is the death of brain cells caused by ischemia in the brain. Ace Therapeutics aims to provide integrated services for basic research and drug development, so as to further investigate the pathogenesis as well as therapeutic approaches to stroke.
Stroke, also known as cerebrovascular event (CVE), cerebrovascular accident (CVA), cerebrovascular lesion (CVI), or sudden onset of encephalopathy, is the death of brain cells caused by ischemia in the brain.
Ischemic stroke refers to the blockage or severe narrowing of cerebral blood vessels due to blood circulation disorders, which decrease cerebral blood perfusion, and then ischemia and hypoxia lead to the death of brain tissues in the area supplied by cerebral blood vessels.
This type of stroke is caused by the rupture of an artery in the brain or on its surface. This type of rupture may be caused by an aneurysm or an abnormality in the vascular system of the brain. The bleeding may occur inside the brain tissue or between the brain and its protective membrane on the outside.
Fig. 1 Exosomes are involved in different ways in ischemic and hemorrhagic strokes. (Lee EC, et al., 2022)
For pharmacological therapy strategies for stroke, the main approach is based on thrombolytic therapies. Nowadays, several new drug therapies, such as oligonucleotide therapies, recombinant peptides, and monoclonal antibody therapies, are now widely used in drug research for stroke.
Overview of Novel Drugs for Stroke
| Drug Name | Drug Target | Original Organization | Drug Phase |
|---|---|---|---|
| Finerenone | Mineralocorticoid Receptor | Bayer AG | Approved |
| Inclisiran | PCSK9 | Alnylam Pharmaceuticals, Inc. | Approved |
| Vicagrel | P2Y12p | Jiangsu Vcare PharmaTech Co., Ltd. | NDA |
| Invimestrocel | / | Athersys, Inc. | Phase 3 |
| Nerinetide | PSD95 | NoNO, Inc. | Phase 3 |
| Asundexian | Coagulation Factor XIa | Bayer AG | Phase 3 |
| Abelacimab | Coagulation Factor XIa | Novartis Pharma AG | Phase 3 |
| Glenzocimab | GPVI | Acticor Biotech SAS | Phase 2/3 |
Ace Therapeutics aims to provide clients with disease model development and research technology services to support basic research and the development of novel therapeutic approaches to stroke.
Research Models
Basic Research
Drug Development
We understand the importance of research models for stroke and are committed to providing customized research model development services.
Custom Animal Model Development Services
Various stroke models have different characteristics, and we are able to recommend and customize appropriate stroke animal models according to our clients' individual research needs.
Transgenic Animal Model Development Services
With the in-depth study of stroke, more and more genes have been reported to be closely associated with the occurrence of stroke. We can provide our clients with construction services of transgenic or knockout animal models, including but not limited to the following genes.
Genetically Engineered Mouse Models
We can provide the following high quality genetically engineered mice for stroke research.
Based on our complete multi-omics research technology platform as well as our pathology and imaging technology platform, we can help our clients deeply investigate the pathogenesis of stroke, identify novel biomarkers for stroke, and evaluate the efficacy of therapeutic drugs.
Novel Biomarker Discovery Services
In recent years, various biomarkers reflecting stroke have been discovered and reported, and these biomarkers provide strong support for stroke preventions and therapy. Based on our multi-omics research platform, we can help our clients discover and characterize novel biomarkers for stroke.
Pathology and Imaging Services
For animal studies of stroke, we can provide researchers with pathology and imaging services for intuitive model validation and efficacy assessment, including but not limited to:
In recent years, more and more novel drug strategies have been applied to the development of stroke drugs, providing new directions for the therapy of stroke. We can provide R&D services for stroke drugs, including but not limited to the following drug types and targets:
R&D Services by Drug Type
R&D Services by Target
Ace Therapeutics is able to provide clients with basic research and novel therapy discovery services aimed at driving new advances in stroke research. If you are interested in our stroke research services, please don't hesitate to contact us.
Ace Therapeutics offers comprehensive solutions and R&D services to researchers worldwide to advance the field of cardiovascular diseases.
We do not provide medical care for patients.
Copyright © Ace Therapeutics. All rights reserved.